Form 4: TScan Therapeutics Executive Zoran Zdraveski Reports Stock Transactions
SEC Form 4
Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics, reports the acquisition and disposition of company stock and stock options on August 23, 2024.
Summary
- On August 23, 2024, Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics, engaged in multiple transactions involving the company's voting common stock and stock options.
- Zdraveski acquired shares through the exercise of stock options at prices of $4.85, $3.27, $1.81, and $2.49.
- He also disposed of 164,686 shares of voting common stock at a weighted average price of $5.7814, with prices ranging from $5.56 to $5.91.
- Following these transactions, Zdraveski directly owns 4,716 shares of voting common stock and holds options to purchase 447,834 additional shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency into the trading activities of key personnel at TScan Therapeutics.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's view of the company's value.
Key Dates
| Date | Description |
|---|---|
| 12/31/2022 | Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| 01/18/2022 | Shares subject to the $4.85 stock option vest over 4 years of service, with 25% vesting after 1 year and the balance in 36 equal monthly installments. |
| 07/25/2022 | Shares subject to the $3.27 stock option vest over 4 years of service, with 25% vesting after 1 year and the balance in 36 equal monthly installments. |
| 02/02/2023 | Shares subject to the $1.81 stock option vest over 4 years of service, with 25% vesting after 1 year and the balance in 36 equal monthly installments. |
| 05/24/2023 | Grant date of stock option with exercise price of $2.49. |
| 06/13/2023 | Approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan. |
| 08/23/2024 | Date of the reported transactions: stock option exercises and stock sale. |
| 08/27/2024 | Date of the Form 4 filing. |
| 01/17/2032 | Expiration date of stock option with exercise price of $4.85. |
| 07/24/2032 | Expiration date of stock option with exercise price of $3.27. |
| 02/01/2033 | Expiration date of stock option with exercise price of $1.81. |
| 06/12/2033 | Expiration date of stock option with exercise price of $2.49. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.